Security Investigation

Cassava Sciences, Inc. (NasdaqCM: SAVA)

46 Days left to seek lead plaintiff status.

Company Name:Cassava Sciences, Inc.
Stock Symbol:NasdaqCM: SAVA
Court:Western District of Texas
Class Period Start:02/07/2024
Class Period End (inclusive):11/24/2024
Filing Deadline:02/10/2025

Contact a Lawyer Now

(877) 515-1850

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA).

Cassava and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On November 25, 2024, the Company disclosed topline results for the first of its two ongoing Phase 3 studies on its leading drug candidate, simufilam, the “ReThink-ALZ” study, that indicated that simufilam failed to meet each of the pre-specified primary, secondary, and exploratory endpoints; in sum, simufilam failed to outperform the placebo.

On this news, the price of Cassava’s shares fell approximately 83%, from a closing price of $26.48 per share on November 22, 2024, to $4.30 per share on November 25, 2024.

If you purchased securities of Cassava and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or fill out the form on this page.

The case is Crocker v. Cassava Sciences, Inc., et al., No. 24-cv-1525.

Click here to read the first filed complaint.